Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 751 to 760 of 1447 total matches.
Growth Hormone for Normal Short Children
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003 (Issue 1169)
Publication
Vol. 45 (Issue 1169)
November 10, 2003
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna ...
The FDA has approved Humatrope, Lilly's brand of recombinant human growth hormone (somatropin), for long-term treatment of children with idiopathic, non-growth-hormone-deficient (NGHD) short stature who are more than 2.25 standard deviations below the mean height for their age and sex. This review describes the clinical studies, adverse effects, and includes a cost table for other brands of somatropin.
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003 (Issue 1169)
Vol. 45 (Issue 1169)
November 10, 2003
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Lowering Plasma Homocysteine
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
Publication
Vol. 45 (Issue 1168)
October 27, 2003
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
Iodine-131 Tositumomab (Bexxar) for Treatment of Lymphoma
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
Publication
Vol. 45 (Issue 1168)
October 27, 2003
EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna ...
Bexxar, a combination of the monoclonal antibody tositumomab and radiolabeled Iodine-131 tositumomab (Corixa Corp/GlaxoSmithKline) has been approved by the FDA for a single treatment of relapsed follicular non-Hodgkin's lymphoma (NHL) in patients who are refractory to rituximab (Rituxan - Medical Letter 1998; 40:65). It is the second radioimmunoconjugate to be approved for refractory NHL; yttrium-90 linked to ibritumomab tiuxetan (Zevalin) was approved in 2002. Tositumomab, like ibritumomab, is a monoclonal antibody of mouse origin that binds to the CD20 antigen present on the surface of >90%...
Alpha-L-Iduronidase (Laronidase; Aldurazyme)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
. 1000 Main Street, New Rochelle, NY 10801 A Nonprofit Publication
Vol. 45 (Issue 1168)
October 27 ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Rosuvastatin - a New Lipid-lowering Drug
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003 (Issue 1167)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1167A ...
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Lp-PLA2: a New Marker of Vascular Risk
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003 (Issue 1167)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1167B ...
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to measure Lp-PLA2 levels. C-reactive protein (CRP), another inflammatory mediator, appears to be a biomarker for coronary disease (MH Shishehbor et al, Cleve Clin J Med 2003; 70:634). The role of Lp-PLA2 testing in determining cardiovascular risk is less clear.
Drugs for Assisted Reproduction
Treatment Guidelines from The Medical Letter • Oct 01, 2003 (Issue 14)
. (ISSN 1541-2784)
Vol. 1 (Issue 14) October 2003
Published by The Medical Letter, Inc.
1000 Main ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Vardenafil (Levitra) for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Sep 29, 2003 (Issue 1166)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1166A ...
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.
Memantine for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1165A ...
Memantine hydrochloride, which has been used to treat dementia in Germany (Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.